Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma
RNA-seq (gene expression) · mouse · 34 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 34 samples: 7 conditions, mostly with about 5 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Reversible dissociation of mitochondrial Complex V balances anabolic and energy-generating needs in canceriScience · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE303515_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1295551 and SRA study SRP603069. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 19 samples read as cases, 5 as controls.
How we read this: 7 replicated groups read from 34 sample titles; they account for 34 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9128358 Control Liver, rep 1 Control Liver,
- GSM9128359 Control Liver, rep 2 Control Liver,
- GSM9128360 Control Liver, rep 3 Control Liver,
- GSM9128361 Control Liver, rep 4 Control Liver,
- GSM9128362 Control Liver, rep 5 Control Liver,
- GSM9128363 Liver, Day 3 post-Myc induction, rep 1 Liver, Day 3 post-Myc i…
- GSM9128364 Liver, Day 3 post-Myc induction, rep 2 Liver, Day 3 post-Myc i…
- GSM9128365 Liver, Day 3 post-Myc induction, rep 3 Liver, Day 3 post-Myc i…
- GSM9128366 Liver, Day 3 post-Myc induction, rep 4 Liver, Day 3 post-Myc i…
- GSM9128367 Liver, Day 3 post-Myc induction, rep 5 Liver, Day 3 post-Myc i…
- GSM9128368 Liver, Day 7 post-Myc induction, rep 1 Liver, Day 7 post-Myc i…
- GSM9128369 Liver, Day 7 post-Myc induction, rep 2 Liver, Day 7 post-Myc i…
- GSM9128370 Liver, Day 7 post-Myc induction, rep 3 Liver, Day 7 post-Myc i…
- GSM9128371 Liver, Day 7 post-Myc induction, rep 4 Liver, Day 7 post-Myc i…
- GSM9128372 Liver, Day 7 post-Myc induction, rep 5 Liver, Day 7 post-Myc i…
- GSM9128373 Liver tumor, Day 21–28 post-Myc induction, replicate 1 Liver tumor, Day 21–28 …
- GSM9128374 Liver tumor, Day 21–28 post-Myc induction, replicate 2 Liver tumor, Day 21–28 …
- GSM9128375 Liver tumor, Day 21–28 post-Myc induction, replicate 3 Liver tumor, Day 21–28 …
- GSM9128376 Liver tumor, Day 21–28 post-Myc induction, replicate 4 Liver tumor, Day 21–28 …
- GSM9128377 Regressing liver tumor, Day 3 post-Myc suppression, replicate 1 Regressing liver tumor,…
- GSM9128378 Regressing liver tumor, Day 3 post-Myc suppression, replicate 2 Regressing liver tumor,…
- GSM9128379 Regressing liver tumor, Day 3 post-Myc suppression, replicate 3 Regressing liver tumor,…
- GSM9128380 Regressing liver tumor, Day 3 post-Myc suppression, replicate 4 Regressing liver tumor,…
- GSM9128381 Regressing liver tumor, Day 3 post-Myc suppression, replicate 5 Regressing liver tumor,…
- GSM9128382 Regressing liver tumor, Day 7 post-Myc suppression, replicate 1 Regressing liver tumor,…
- GSM9128383 Regressing liver tumor, Day 7 post-Myc suppression, replicate 2 Regressing liver tumor,…
- GSM9128384 Regressing liver tumor, Day 7 post-Myc suppression, replicate 3 Regressing liver tumor,…
- GSM9128385 Regressing liver tumor, Day 7 post-Myc suppression, replicate 4 Regressing liver tumor,…
- GSM9128386 Regressing liver tumor, Day 7 post-Myc suppression, replicate 5 Regressing liver tumor,…
- GSM9128387 Recurrent liver tumor, post-Myc reactivation after long-term regression, replicate 1 Recurrent liver tumor, …
- GSM9128388 Recurrent liver tumor, post-Myc reactivation after long-term regression, replicate 2 Recurrent liver tumor, …
- GSM9128389 Recurrent liver tumor, post-Myc reactivation after long-term regression, replicate 3 Recurrent liver tumor, …
- GSM9128390 Recurrent liver tumor, post-Myc reactivation after long-term regression, replicate 4 Recurrent liver tumor, …
- GSM9128391 Recurrent liver tumor, post-Myc reactivation after long-term regression, replicate 5 Recurrent liver tumor, …
- GSE295796 Characterising transcriptional changes throughout c-MYC-driven tumorigenesis in the mammary gland (MMTV-cMYC mouse model) 30 samples shares c-myc-driven, changes
- GSE227650 Changes in adaptive immunity and increased neuroinflammation are key processes in ageing EAE: a road to develop new therapeutic strategies for elderly MS patients 40 samples shares adaptive, changes
- GSE249325 Development Of Pre-Clinical Murine Models For Fibrolamellar Hepatocellular Carcinoma 19 samples shares hepatocellular
- GSE271709 The Alb-R26Met liver cancer mouse model recapitulates molecular features and heterogeneity of hepatocellular carcinoma patients 18 samples shares hepatocellular
- GSE273892 Role of metabolism in sorafenib-resistance hepatocellular carcinoma cellular model. 16 samples shares hepatocellular
- GSE302836 Loss of Hepatocyte PI3Ka Protects Mice from Hepatocellular Carcinoma in association with altered lipid metabolism gene expression 42 samples shares hepatocellular
- GSE230972 Loss of cisPTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinoma 27 samples shares hepatocellular
- GSE308568 The origin of hepatocellular carcinoma is regulated by metabolic zonation [RNA-seq] 26 samples shares hepatocellular
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.